zumindest gröbere Gerüchte...morgen ist Mittwoch...Judgement Day
füxlein
füxlein
Top-News
Andrx mit Bilanzfälschung....
Beiträge:
6
Zugriffe: 449 / Heute: 1
Zugriffe: 449 / Heute: 1
bei Andrx ist es etwas anders. Da haben keine Vorstände Bilanzen aufpoliert, sondern ein Mitarbeiter hat lediglich einige Dinge falsch gebucht, wodurch nun ein wesentlich geringerer Verlust anfällt!!!
Grüße
Pavian
(©BörseGo - www.boerse-go.de)
Andrx habe als Folge eines internen Audits herausgefunden, dass ein Mitarbeiter eines Tochterunternehmens bestimmte Einträge bei der Verbuchung von Verbindlichkeiten falsch getätigt habe. Die Verbindlichkeiten, die zum 30. Juli bei 103.6 Millionen Dollar angegeben wurden, könnten um 15 Millionen zu hoch liegen, hieß es.
Grüße
Pavian
(©BörseGo - www.boerse-go.de)
Andrx habe als Folge eines internen Audits herausgefunden, dass ein Mitarbeiter eines Tochterunternehmens bestimmte Einträge bei der Verbuchung von Verbindlichkeiten falsch getätigt habe. Die Verbindlichkeiten, die zum 30. Juli bei 103.6 Millionen Dollar angegeben wurden, könnten um 15 Millionen zu hoch liegen, hieß es.
dass noch weitere Fehlbuchungen/Fälschungen auftauchen. Und dann vielleicht negative...
Grüße
Pavian
Grüße
Pavian
-- Raymond James downgrades to MKT PERFORM from Strong Buy after the co indicated it may have overstated earnings by as much as 4% since the beginning of 1999. Firm estimates an effect of as much as $015 a share compared with earnings of about $3.40 reported since 1999. Believes the accounting irregularities will diminish the valuation investors are willing to apply to ADRX
Andrx Announces Internal Investigation Regarding Aging of Certain Accounts Receivable
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Aug. 12, 2002--Andrx Corporation (Nasdaq:ADRX - News) today announced that, as a result of its internal audit process, management has learned that an employee of one of its subsidiaries appears to have altered certain accounting records pertaining to accounts receivable balances and aging relating to its pharmaceutical and distribution operations, thereby potentially affecting Andrx's allowance for doubtful accounts. Andrx is actively investigating the matter, but does not believe that the employee's actions will impact the Company's business or financial condition in any substantial manner. Based upon its investigation, it appears that the Company's previously announced net accounts receivable of $103.6 million as of June 30, 2002, may have been overstated by as much as $15 million relating to the period from January 1, 1999 to date. These amounts represent less than 1% of the Company's approximate $2 billion of net product sales during the total relevant period. Determination of the final amount of net accounts receivable will be subject to completion of the Company's investigation. ADVERTISEMENT
Andrx anticipates that it will request a five-calendar day extension to file its Form 10-Q for the quarter ended June 30, 2002. Such report shall reflect the Company's determination as to how to proceed, including the effect, if any, on certain prior reported periods.
As previously announced, as of June 30, 2002, the Company had approximately $390 million in working capital, $630 million in total stockholders' equity and no long-term debt.
Conference Call
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Aug. 12, 2002--Andrx Corporation (Nasdaq:ADRX - News) today announced that, as a result of its internal audit process, management has learned that an employee of one of its subsidiaries appears to have altered certain accounting records pertaining to accounts receivable balances and aging relating to its pharmaceutical and distribution operations, thereby potentially affecting Andrx's allowance for doubtful accounts. Andrx is actively investigating the matter, but does not believe that the employee's actions will impact the Company's business or financial condition in any substantial manner. Based upon its investigation, it appears that the Company's previously announced net accounts receivable of $103.6 million as of June 30, 2002, may have been overstated by as much as $15 million relating to the period from January 1, 1999 to date. These amounts represent less than 1% of the Company's approximate $2 billion of net product sales during the total relevant period. Determination of the final amount of net accounts receivable will be subject to completion of the Company's investigation. ADVERTISEMENT
Andrx anticipates that it will request a five-calendar day extension to file its Form 10-Q for the quarter ended June 30, 2002. Such report shall reflect the Company's determination as to how to proceed, including the effect, if any, on certain prior reported periods.
As previously announced, as of June 30, 2002, the Company had approximately $390 million in working capital, $630 million in total stockholders' equity and no long-term debt.
Conference Call
Es gibt keine neuen Beiträge.
